A little more than two years after JetZero revealed ambitious plans to challenge the Airbus- Boeing air transport duopoly by ...

T he Boeing 767-300ER has long been a key part of medium- and long-haul operations for airlines across the world. It belongs ...

A Delta Air Lines flight that crashed in Toronto last month was descending at a high rate of speed in strong winds when it landed, flipped over after the collapse of its right landing gear and ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced positive ...

BALLERUP, Denmark, June 3, 2025--- LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept DELTA NEXT trial. The trial aims to evaluate ...

Streamlined U.S.-only study design builds on Phase 2 momentum for IHL-42X in obstructive sleep apneaNEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc ...

“Our new global HQ and plant represents a pivotal moment in DELTA Coatings’ evolution since its inception over 20 years ago,” said Belvin Marx, General Manager at DELTA Coatings International. “With ...

98.52% secure Plus One allotment in main phase A total of 3.12 lakh students have got allotment till now; 87,928 students got fresh allotment in third list alone Published - June 15, 2025 08:56 pm ...

Roche said in a statement that the experimental antibiotic zosurabalpin, jointly developed with Harvard University, would be tested against acinetobacter baumannii, relying on a new mode of action ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

“We are thrilled to bring forward the first phase 3 results from our clinical development program evaluating enlicitide, which, if approved, would be the first marketed oral PCSK9 inhibitor in ...

Novocure NVCR recently announced positive top-line results from its pivotal Phase 3 PANOVA-3 trial, evaluating Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab ...